DRUG
Eloralintide
Administered subcutaneously (SC)
Status
Completed
Phase
Phase 1
Enrollment
30
Locations
1
Results
Not posted
Publications
0
Study summary
The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it. The study will last approximately 10 weeks excluding a screening period.
Interventions
DRUG
Administered subcutaneously (SC)
DRUG
Administered SC
Timeline
First posted
Apr 8, 2025
Study start
Apr 21, 2025
Primary completion
Sep 9, 2025
Study completion
Sep 9, 2025
Results posted
Not reported
Registry updated
Nov 19, 2025
Outcomes
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame · Baseline to Study Completion (Up to 10 Weeks)
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Eloralintide
Time frame · Baseline to Study Completion (Up to 10 Weeks)
PK:Cmax of Eloralintide
PK: Area Under the Concentration Versus Time Curve (AUC) of Eloralintide
Time frame · Baseline to Study Completion (Up to 10 Weeks)
PK: AUC of Eloralintide
Eligibility
Inclusion Criteria: * Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China * Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed * Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization * Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator * Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²) Exclusion Criteria: * Are pregnant, or intend to become pregnant or to breastfeed during the study * Have known allergies to related compounds of eloralintide * Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator: * Supine BP \> 160/90 millimeter mercury (mmHg) * Supine pulse rate \< 50 or \> 100 beats per minute (bpm) * Orthostatic hypotension * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs * Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history * Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study * Have a history of chronic medical conditions involving the heart, liver, or kidneys * Have a medical history or current evidence of clinically significant cardiac condition
Study locations
Singapore. Showing up to 24 locations stored in the fast local snapshot.
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Eli Lilly · Obesity · Overweight
Phase 1
Not yet recruiting
56
2026-07
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Eli Lilly · Obesity · Overweight
Phase 2
Active, not recruiting
367
2026-07
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
200
2026-07
Eli Lilly · Overweight · Obesity
Phase 3
Recruiting
1,035
2026-07
Eli Lilly · Obesity · Overweight
Phase 3
Recruiting
1,980
2026-07
Eli Lilly · Osteoarthritis · Overweight or Obesity
Phase 3
Recruiting
900
2026-07
Eli Lilly · Sleep Apnea, Obstructive · Obesity
Phase 3
Recruiting
800
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.